Compare WCCB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WCCB | DCTH |
|---|---|---|
| Founded | 2004 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.6M | 578.4M |
| IPO Year | 2026 | 2015 |
| Metric | WCCB | DCTH |
|---|---|---|
| Price | $60.93 | $18.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $73.50 | $28.60 |
| AVG Volume (30 Days) | 85.7K | ★ 716.2K |
| Earning Date | 09-23-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ 4.17 | 0.21 |
| Revenue | N/A | N/A |
| Revenue This Year | $7.07 | $36.66 |
| Revenue Next Year | $6.44 | $20.12 |
| P/E Ratio | ★ $14.62 | $91.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.91 | $8.49 |
| 52 Week High | $64.32 | $22.51 |
| Indicator | WCCB | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 57.91 |
| Support Level | $59.68 | $14.14 |
| Resistance Level | $61.95 | $22.51 |
| Average True Range (ATR) | 1.35 | 1.19 |
| MACD | -0.36 | 0.13 |
| Stochastic Oscillator | 15.56 | 55.66 |
West Coast Community Bancorp is a bank holding company. Through its banking subsidiary, it offers a full range of commercial and personal banking services to residents and businesses in Santa Cruz County and adjacent Monterey, San Luis Obispo, and Santa Clara counties. Its products and service offerings include mobile banking, credit and debit cards, treasury management, deposit products, such as checking, savings, and term certificate accounts, and lending products such as commercial, commercial real estate, construction, multifamily, municipal, asset-backed loans, etc. Its lending products also include various government guarantee programs such as Small Business Administration (SBA) and 504 programs, as well as U.S. Department of Agriculture (USDA) programs.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.